Advanced Technologies in Marine Drug Development Market Size, Report by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Advanced Technologies in Marine Drug Development Market

5.1. COVID-19 Landscape: Advanced Technologies in Marine Drug Development Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Advanced Technologies in Marine Drug Development Market, By Technology Type

8.1. Advanced Technologies in Marine Drug Development Market, by Technology Type

8.1.1. Genomic and Metagenomic Tools

8.1.1.1. Market Revenue and Forecast

8.1.2. Analytical and Screening Technologies

8.1.2.1. Market Revenue and Forecast

8.1.3. Bioengineering and Synthesis

8.1.3.1. Market Revenue and Forecast

8.1.4. Marine Bioprocessing and Extraction

8.1.4.1. Market Revenue and Forecast

Chapter 9. Global Advanced Technologies in Marine Drug Development Market, By Source Organism

9.1. Advanced Technologies in Marine Drug Development Market, by Source Organism

9.1.1. Marine Bacteria

9.1.1.1. Market Revenue and Forecast

9.1.2. Marine Fungi

9.1.2.1. Market Revenue and Forecast

9.1.3. Marine Algae (Macro and Microalgae)

9.1.3.1. Market Revenue and Forecast

9.1.4. Marine Invertebrates

9.1.4.1. Market Revenue and Forecast

9.1.5. Marine Vertebrates (e.g., Fish-derived)

9.1.5.1. Market Revenue and Forecast

9.1.6. Others

9.1.6.1. Market Revenue and Forecast

Chapter 10. Global Advanced Technologies in Marine Drug Development Market, By Therapeutic Application

10.1. Advanced Technologies in Marine Drug Development Market, by Therapeutic Application

10.1.1. Oncology

10.1.1.1. Market Revenue and Forecast

10.1.2. Infectious Diseases

10.1.2.1. Market Revenue and Forecast

10.1.3. Inflammatory and Autoimmune Diseases

10.1.3.1. Market Revenue and Forecast

10.1.4. Neurological Disorders

10.1.4.1. Market Revenue and Forecast

10.1.5. Metabolic Disorders

10.1.5.1. Market Revenue and Forecast

10.1.6. Others (Cardiovascular, Rare Diseases)

10.1.6.1. Market Revenue and Forecast

Chapter 11. Global Advanced Technologies in Marine Drug Development Market, By Development Stage

11.1. Advanced Technologies in Marine Drug Development Market, by Development Stage

11.1.1. Discovery & Preclinical

11.1.1.1. Market Revenue and Forecast

11.1.2. Clinical Trials

11.1.2.1. Market Revenue and Forecast

11.1.3. Commercialized Drugs

11.1.3.1. Market Revenue and Forecast

Chapter 12. Global Advanced Technologies in Marine Drug Development Market, By End Use

12.1. Advanced Technologies in Marine Drug Development Market, by End Use

12.1.1. Pharmaceutical & Biotechnology Companies

12.1.1.1. Market Revenue and Forecast

12.1.2. Academic & Research Institutes

12.1.2.1. Market Revenue and Forecast

12.1.3. Marine Biotech Startups

12.1.3.1. Market Revenue and Forecast

12.1.4. Contract Research Organizations (CROs)

12.1.4.1. Market Revenue and Forecast

12.1.5. Others (Government Marine Labs, Oceanography Institutes)

12.1.5.1. Market Revenue and Forecast

Chapter 13. Global Advanced Technologies in Marine Drug Development Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Technology Type

13.1.2. Market Revenue and Forecast, by Source Organism

13.1.3. Market Revenue and Forecast, by Therapeutic Application

13.1.4. Market Revenue and Forecast, by Development Stage

13.1.5. Market Revenue and Forecast, by End Use

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Technology Type

13.1.6.2. Market Revenue and Forecast, by Source Organism

13.1.6.3. Market Revenue and Forecast, by Therapeutic Application

13.1.6.4. Market Revenue and Forecast, by Development Stage

13.1.6.5. Market Revenue and Forecast, by End Use

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Technology Type

13.1.7.2. Market Revenue and Forecast, by Source Organism

13.1.7.3. Market Revenue and Forecast, by Therapeutic Application

13.1.7.4. Market Revenue and Forecast, by Development Stage

13.1.7.5. Market Revenue and Forecast, by End Use

13.2. Europe

13.2.1. Market Revenue and Forecast, by Technology Type

13.2.2. Market Revenue and Forecast, by Source Organism

13.2.3. Market Revenue and Forecast, by Therapeutic Application

13.2.4. Market Revenue and Forecast, by Development Stage

13.2.5. Market Revenue and Forecast, by End Use

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Technology Type

13.2.6.2. Market Revenue and Forecast, by Source Organism

13.2.6.3. Market Revenue and Forecast, by Therapeutic Application

13.2.7. Market Revenue and Forecast, by Development Stage

13.2.8. Market Revenue and Forecast, by End Use

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Technology Type

13.2.9.2. Market Revenue and Forecast, by Source Organism

13.2.9.3. Market Revenue and Forecast, by Therapeutic Application

13.2.10. Market Revenue and Forecast, by Development Stage

13.2.11. Market Revenue and Forecast, by End Use

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Technology Type

13.2.12.2. Market Revenue and Forecast, by Source Organism

13.2.12.3. Market Revenue and Forecast, by Therapeutic Application

13.2.12.4. Market Revenue and Forecast, by Development Stage

13.2.13. Market Revenue and Forecast, by End Use

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Technology Type

13.2.14.2. Market Revenue and Forecast, by Source Organism

13.2.14.3. Market Revenue and Forecast, by Therapeutic Application

13.2.14.4. Market Revenue and Forecast, by Development Stage

13.2.15. Market Revenue and Forecast, by End Use

13.3. APAC

13.3.1. Market Revenue and Forecast, by Technology Type

13.3.2. Market Revenue and Forecast, by Source Organism

13.3.3. Market Revenue and Forecast, by Therapeutic Application

13.3.4. Market Revenue and Forecast, by Development Stage

13.3.5. Market Revenue and Forecast, by End Use

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Technology Type

13.3.6.2. Market Revenue and Forecast, by Source Organism

13.3.6.3. Market Revenue and Forecast, by Therapeutic Application

13.3.6.4. Market Revenue and Forecast, by Development Stage

13.3.7. Market Revenue and Forecast, by End Use

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Technology Type

13.3.8.2. Market Revenue and Forecast, by Source Organism

13.3.8.3. Market Revenue and Forecast, by Therapeutic Application

13.3.8.4. Market Revenue and Forecast, by Development Stage

13.3.9. Market Revenue and Forecast, by End Use

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Technology Type

13.3.10.2. Market Revenue and Forecast, by Source Organism

13.3.10.3. Market Revenue and Forecast, by Therapeutic Application

13.3.10.4. Market Revenue and Forecast, by Development Stage

13.3.10.5. Market Revenue and Forecast, by End Use

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Technology Type

13.3.11.2. Market Revenue and Forecast, by Source Organism

13.3.11.3. Market Revenue and Forecast, by Therapeutic Application

13.3.11.4. Market Revenue and Forecast, by Development Stage

13.3.11.5. Market Revenue and Forecast, by End Use

13.4. MEA

13.4.1. Market Revenue and Forecast, by Technology Type

13.4.2. Market Revenue and Forecast, by Source Organism

13.4.3. Market Revenue and Forecast, by Therapeutic Application

13.4.4. Market Revenue and Forecast, by Development Stage

13.4.5. Market Revenue and Forecast, by End Use

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Technology Type

13.4.6.2. Market Revenue and Forecast, by Source Organism

13.4.6.3. Market Revenue and Forecast, by Therapeutic Application

13.4.6.4. Market Revenue and Forecast, by Development Stage

13.4.7. Market Revenue and Forecast, by End Use

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Technology Type

13.4.8.2. Market Revenue and Forecast, by Source Organism

13.4.8.3. Market Revenue and Forecast, by Therapeutic Application

13.4.8.4. Market Revenue and Forecast, by Development Stage

13.4.9. Market Revenue and Forecast, by End Use

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Technology Type

13.4.10.2. Market Revenue and Forecast, by Source Organism

13.4.10.3. Market Revenue and Forecast, by Therapeutic Application

13.4.10.4. Market Revenue and Forecast, by Development Stage

13.4.10.5. Market Revenue and Forecast, by End Use

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Technology Type

13.4.11.2. Market Revenue and Forecast, by Source Organism

13.4.11.3. Market Revenue and Forecast, by Therapeutic Application

13.4.11.4. Market Revenue and Forecast, by Development Stage

13.4.11.5. Market Revenue and Forecast, by End Use

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Technology Type

13.5.2. Market Revenue and Forecast, by Source Organism

13.5.3. Market Revenue and Forecast, by Therapeutic Application

13.5.4. Market Revenue and Forecast, by Development Stage

13.5.5. Market Revenue and Forecast, by End Use

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Technology Type

13.5.6.2. Market Revenue and Forecast, by Source Organism

13.5.6.3. Market Revenue and Forecast, by Therapeutic Application

13.5.6.4. Market Revenue and Forecast, by Development Stage

13.5.7. Market Revenue and Forecast, by End Use

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Technology Type

13.5.8.2. Market Revenue and Forecast, by Source Organism

13.5.8.3. Market Revenue and Forecast, by Therapeutic Application

13.5.8.4. Market Revenue and Forecast, by Development Stage

13.5.8.5. Market Revenue and Forecast, by End Use

Chapter 14. Company Profiles

14.1. PharmaMar S.A.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Biosortia Pharmaceuticals

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Marinomed Biotech AG

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Nereus Pharmaceuticals (acquired by Triphase)

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Aker BioMarine

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. SeaLife Pharma

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. GlycoMar

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Cyanotech Corporation

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Sirenas Marine Discovery

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. MycoMedica Life Sciences

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The major players in the advanced technologies in marine drug development market include PharmaMar S.A., Biosortia Pharmaceuticals, Marinomed Biotech AG, Nereus Pharmaceuticals (acquired by Triphase), Aker BioMarine, SeaLife Pharma, GlycoMar, Sirenas Marine Discovery, MycoMedica Life Sciences, Ocean Hugger Biotech, Aquapharm BioDiscovery, MicroBioGen, Enveda Biosciences, Salipro Biotech AB, Celgene (BMS, via marine natural product work), Neuropharmex Ltd., Axxam S.p.A., Seventure Partners (marine biotech venture arm), and SinRx Therapeutics.

The driving factors of the advanced technologies in marine drug development market are the rising demand for natural therapeutics, ongoing technological advancements, and the untapped potential of marine biodiversity.

North America region will lead the global advanced technologies in marine drug development market during the forecast period 2025 to 2034.